Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.

Thrombosis and haemostasis - 1 Aug 1998

Galli M, Duca F, Ruggeri L, Finazzi G, Negri B, Moia M

Abstract excerpt

The R506Q mutation ("Factor V Leiden") is responsible for the resistance to activated Protein C (aPCR), that is evaluated by coagulation tests. Such tests cannot be used in patients with lupus anticoagulants (LAs), due to the interfering effect exerted by these antibodies on "in vitro" phospholip...

Topics

Activated Protein C Resistance
Adult
Blood Coagulation Tests
Evaluation Studies as Topic
Factor V
Female
Humans
Lupus Coagulation Inhibitor
Male
Mutation
Polymerase Chain Reaction
Predictive Value of Tests
Sensitivity and Specificity

Source

Open in PubMed

Identifiers

PMID: 9716147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9716147-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics